Patient Insight and Treatment Expectations in Erectile Dysfunction
In the literature, a strong preference towards pharmacological management with oral phosphodiesterase type 5 (PDE5) inhibitors has been demonstrated in men with erectile dysfunction (ED) versus other methods. However, following pharmacological management, a large proportion of men with ED discontinu...
Main Author: | Hartmut Porst |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2016-04-01
|
Series: | European Medical Journal |
Subjects: | |
Online Access: | https://emj.emg-health.com/wp-content/uploads/sites/2/2018/01/Patient-Insight-and-Treatment-Expectations-in-Erectile-Dysfunction.pdf |
Similar Items
-
Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
by: Bang-Ping Jiann
Published: (2016-06-01) -
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
by: Yatan Pal Singh Balhara, et al.
Published: (2015-01-01) -
Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction
by: Safar Israilovich Gamidov, et al.
Published: (2009-10-01) -
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma
by: Jenny Z. Wang, et al.
Published: (2019-09-01) -
A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice
by: Vincenzo Mirone, et al.
Published: (2016-07-01)